The goal of the Pediatric Malignancies Program is to improve, through basic and clinical translational research, the outcome for children with cancer. Pediatric cancers are unique in their morphology, tissues of origin and behavior. They provide an opportunity to understand the link between normal development and the aberrations of malignancy, the interactions of genetics and environment, and the late effects of treatment.
The aims of the program are the following: (1) to elucidate the molecular pathogenesis of childhood cancer by identifying important genes, proteins and pathways;(2) to translate this information into improved diagnosis, classification, prediction of outcome, and treatment selection and epidemiological studies;(3) to develop and conduct clinical Phase I, II and III trials to improve survival;(4) to study the late effects of therapy and improve the quality of life for survivors;and (5) to train fellows, residents and students in pediatric malignancies and mentor junior faculty with basic and clinical research training awards. The Pediatric Malignancies Program has 25 members from 10 different departments. The main research interests of the Pediatric Malignancies Program are molecular and genomic studies of pediatric malignancies (particularly neuroblastoma, CMS tumors, leukemias and retinoblastoma), developmental therapeutics in neuroblastoma, brain tumors, and leukemia, and late effects and epidemiology of childhood cancer. The goals of the Program are enhanced by close synergy with Cancer Center Programs such as Hematopoietic Malignancies, Neurologic Oncology, and Tobacco Control, as well as many interactions with scientists in other, basic science Programs, such as Cancer and Immunity, Cell Cycling and Signaling, and Cancer Genetics, and with the Cores. The Program has $4,444,595 Total peer reviewed support for the last budget year. The Program has 17% intra-programmatic and 40% inter-programmatic publications. PERFORMANCE SITE(S) (organization, city, state) UCSF Comprehensive Cancer Center San Francisco, California PHS 398/2590 (Rev. 09/04) Page Pediatric Malignancies Program

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Ryu, Jae Kyu; Rafalski, Victoria A; Meyer-Franke, Anke et al. (2018) Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19:1212-1223
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Tat, David; Kenfield, Stacey A; Cowan, Janet E et al. (2018) Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSUREā„¢). Prostate 78:32-39
Guydish, Joseph; Tajima, Barbara; Le, Thao et al. (2018) Do cigarette graphic warnings encourage smokers to attend a smoking cessation programme: a quasi-experimental study. Tob Control 27:43-49
Dvorak, Christopher C; Satwani, Prakash; Stieglitz, Elliot et al. (2018) Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatr Blood Cancer 65:e27034
Fan, Qi Wen; Nicolaides, Theodore P; Weiss, William A (2018) Inhibiting 4EBP1 in Glioblastoma. Clin Cancer Res 24:14-21

Showing the most recent 10 out of 192 publications